Arcutis Biotherapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$15.9M
Doctors Paid
12,313
Transactions
87,026
2024 Total
$6.6M
Payment Breakdown by Category
Research$6.6M (41.5%)
Consulting$4.8M (30.4%)
Food & Beverage$1.9M (12.2%)
Travel$672,078 (4.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.6M | 2,052 | 41.5% |
| Consulting Fee | $4.8M | 1,936 | 30.4% |
| Food and Beverage | $1.9M | 80,326 | 12.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.9M | 684 | 11.7% |
| Travel and Lodging | $672,078 | 1,890 | 4.2% |
| Grant | $14,500 | 3 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,053 | 26 | 0.0% |
| Education | $1,443 | 109 | 0.0% |
Payments by Type
General
$9.3M
84,974 transactions
Research
$6.6M
2,052 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis | $2.5M | 5 | 980 |
| A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis | $1.7M | 3 | 431 |
| A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis | $918,457 | 7 | 302 |
| A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata | $787,706 | 0 | 188 |
| A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Scalp and Body Psoriasis (ARRECTOR) | $256,385 | 3 | 69 |
| A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects with Chronic Plaque Psoriasis who have Completed Preceding Studies ARQ-151-301 or ARQ-151-302 | $189,623 | 1 | 55 |
| A Phase 1, Randomized, Open-label Study to Determine Safety and Pharmacokinetics of the Topical Application of ARQ-151 Cream in Healthy Japanese Volunteers | $188,198 | 0 | 3 |
| A Phase 2, Multicenter, Open-Label Study of the Long-Term Safety of ARQ-154 Foam 0.3% in Subjects with Seborrheic Dermatitis | $78,117 | 1 | 12 |
| A Phase 3, 8-Week, Parallel Group, Double blind, Vehicle-controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic Dermatitis (STRATUM) | $39,802 | 1 | 10 |
| A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis | $1,236 | 0 | 1 |
| A Phase 2a, Proof of Concept, 24-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects with Non-Segmental Facial Vitiligo | $102.00 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Amy Spizuoco, D.o, D.O | Dermatology | New York, NY | $80,528 | $0 |
| Ms. Melodie Young, Msn, MSN | Nurse Practitioner | Dallas, TX | $78,335 | $0 |
| Dr. Peter Lio, M.d, M.D | Dermatology | Chicago, IL | $76,438 | $0 |
| Craig Teller, M.d, M.D | Dermatology | Bellaire, TX | $76,412 | $0 |
| Dr. Marcjonathan Serota, M.d, M.D | Allergy & Immunology | Littleton, CO | $70,703 | $0 |
| Mr. Tomas Chao, Pa, PA | Medical | Woodstock, GA | $68,744 | $0 |
| Dr. Todd Schlesinger, M.d, M.D | Dermatology | Charleston, SC | $67,457 | $0 |
| Dale Schaefer, Md, MD | Dermatology | Austin, TX | $67,081 | $0 |
| Scott Guenthner, Md, MD | Dermatology | Plainfield, IN | $66,295 | $0 |
| Dr. Heather Woolery-Lloyd, Md, MD | Dermatology | Miami, FL | $62,784 | $0 |
| Dr. Edward Lain, M.d, M.D | Dermatology | Austin, TX | $60,263 | $0 |
| Abel Jarell, Md, MD | Dermatology | Portsmouth, NH | $59,027 | $0 |
| Dr. Jennifer Cather, M.d, M.D | Dermatology | Dallas, TX | $58,458 | $0 |
| Mrs. Jennifer Davisson, Pa-C, PA-C | Physician Assistant | Kansas City, MO | $57,767 | $0 |
| Andrea Nguyen, Pa-C, PA-C | Physician Assistant | Irvine, CA | $56,655 | $0 |
| Firas Hougeir, M.d, M.D | MOHS-Micrographic Surgery | Douglasville, GA | $56,161 | $0 |
| Adelaide Hebert, M.d, M.D | Pediatric Dermatology | Bellaire, TX | $55,403 | $0 |
| Alex Glazer, M.d, M.D | Dermatopathology | Buffalo Grove, IL | $54,921 | $0 |
| Dr. William Cragun, M.d, M.D | Dermatology | San Antonio, TX | $54,087 | $0 |
| Dr. Jeffrey Laduca, Ph. D, Md, PH. D, MD | Specialist | Auburn, NY | $53,931 | $0 |
| Dr. Jeffrey Crowley, M.d, M.D | MOHS-Micrographic Surgery | Bakersfield, CA | $53,793 | $0 |
| Dr. Lawrence Green, Md, MD | Procedural Dermatology | Rockville, MD | $53,032 | $0 |
| Dr. Ronald Bernardin, Md, MD | Dermatology | Voorhees, NJ | $52,600 | $0 |
| Dr. Diego Dasilva, Md, MD | Dermatology | Virginia Beach, VA | $51,686 | $0 |
| Mr. Ali Shahbaz, Md, MD | Dermatology | Austin, TX | $49,190 | $0 |
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. has made $15.9M in payments to 12,313 healthcare providers, recorded across 87,026 transactions in the CMS Open Payments database. In 2024, the company paid $6.6M. The top product by payment volume is Zoryve ($5.9M).
Payments were distributed across 118 medical specialties. The top specialty by payment amount is Dermatology ($5.3M to 4,558 doctors).
Payment categories include: Food & Beverage ($1.9M), Consulting ($4.8M), Research ($6.6M), Travel & Lodging ($672,078).
Arcutis Biotherapeutics, Inc. is associated with 1 products in the CMS Open Payments database.